New biomarker for bowel cancer could help predict if disease will spread

July 24, 2013

Scientists have identified a protein that could play a crucial role in recognising whether bowel cancer patients need chemotherapy as there is a high risk of their bowel cancer spreading, according to a new study1 published in the British Journal of Cancer.

Scientists at the University of Southampton, part-funded by the Medical Research Council and Cancer Research UK, found that patients with low levels of the protein, known as FOXO32, had an increased risk of their cancer spreading to other parts of the body.

By comparing levels of FOXO3 in tissue samples from patients with different stages of the researchers found the protein was a good predictor of how aggressive a tumour is – decreasing levels of the protein were linked to more aggressive cancers.

Mr Marc Bullock, study author, MRC Clinical Research Training Fellow and bowel cancer surgeon at Southampton General Hospital, said: "Our findings suggest that looking at levels of FOXO3 could help single out which patients need extra treatment to help stop their cancer from coming back, as well as being a good potential target for drug development. Although other studies have looked at the role of FOXO3 in stopping tumours growing, this is the first time that such a clear link between levels of the and tumour growth has been identified."

Mr Alexander Mirnezami, co-author and bowel at Southampton General Hospital said: "As our research continues, we hope to identify lots of other new biomarkers that can help us adapt treatments based on individual patients' tumour characteristics as part of a personalised approach to ."

Dr Julie Sharp, senior science communications manager at Cancer Research UK, said: "This fascinating new finding could help doctors tackle the problem of bowel cancer spread. Although levels of FOXO3 alone are not enough to accurately predict whether a patient's cancer will return, the authors' highlight several other potential that, alongside FOXO3, could offer a powerful new tool to help doctors decide the best way to treat patients."

Explore further: Protein levels could predict if bowel cancer patients will benefit from Avastin

Related Stories

Family history of bowel cancer increases odds of survival

March 20, 2013

A new study that combines genetic information on bowel cancer with NHS patient outcome data has found a link between family history of the disease and a better chance of survival, published in the British Journal of Cancer.

New type of bowel cancer discovered

April 15, 2013

(Medical Xpress)—A unique sub-type of bowel cancer has been discovered which has a worse outcome than other types of colon cancer and is resistant to certain targeted treatments, according to research published today in ...

Alternative target for breast cancer drugs

July 19, 2013

Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published today ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.